Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs Atezolizumab + Bevacizumab in PD-L1+ Metastatic NSCLC
NCT03896074Phase 2Active, not recruiting
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Mar 2020
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Started Mar 2020; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03896074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896074.